Educazione

• 2019     Specializzazione in Ematologia, 60/60 e lode, Università di Firenze, Italia. Tesi: Clinical, Molecular and Prognostic Correlates of Number, Type and Intragenic Localization of TET2 Mutations in Chronic Myelomonocytic Leukemia. Relatore/Correlatore: A.M.Vannucchi/A. Bosi
• 2019     Research Trainee presso il Cancer Center-Hematology della Mayo Clinic, Rochester, MN (USA). Tutors: Ayalew Teffer/Mrinal Patnaik
• 2015     Laurea Magistrale in Medicina e Chirurgia, 110/110 e lode, Università degli studi di Padova, Italia. Tesi: Le Mutazioni di CALR: Messa a Punto del Sequenziamento e Implicazioni Cliniche nella Trombocitemia Essenziale. Relatore: Prof. M.L. Randi

Esperienze Professionali

• 2021 – In corso     Ricercatore a tempo determinato tipo a), Centro di Ricerca e Innovazione per le Malattie Mieloproliferative (CRIMM), AOU Careggi, Università di Firenze, Italia
•  2020 - 2021         Assegnista di ricerca, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative (CRIMM), AOU Careggi, Università di Firenze, Italia

Interessi scientifici

• Ricerca clinica e sperimentale nell’ambito delle neoplasie mieloproliferative croniche Philadelphia-.
• Caratterizzazione molecolare del profilo di espressione genica nelle neoplasie mieloproliferative.
• Studi preclinici e clinici con farmaci innovativi in pazienti con neoplasie mieloproliferative.

Competenze

• Diagnosi e trattamento di pazienti con malattie ematologiche oncologiche e non, in particolare neoplasie mieloproliferative croniche.
• Esperienza in BSL1, BSL2 e camere bianche, preparazione di colture cellulari in sospensione e adesione (linee cellulari e cellule primarie del paziente), isolamento di popolazioni cellulari specifiche mediante separazione in gradiente di densità, estrazione di acidi nucleici da tessuti, pellet cellulari e sangue intero, purificazione e quantificazione, immunoprecipitazione e western blotting, ELISA e immunoistochimica, PCR, qRT-PCR, HRM, sequenziamento di Sanger.
• Utilizzo di software statistici (SPSS, GraphPad, JMP, R) e strumenti bioinformatici. Buona conoscenza dei database online di genomica, trascrittomica e proteomica.
• Ottime capacità di relazione e collaborazione con tutte le figure professionali. Ottima capacità di sviluppare e discutere problemi e risultati di attività cliniche e di ricerca, organizzare autonomamente il lavoro clinico e sperimentale e definire le priorità entro le scadenze stabilite.

Didattica

• 2020-In corso     Corso di Ematologia, Facoltà di Medicina e Chirurgia, Università di Firenze, Italia
• 2020-In corso     Corso di Ematologia, Facoltà di Biotecnologie, Università di Firenze, Italia
• 2020-In corso     Corso di Ematologia, Facoltà di Infermieristica, Università di Firenze, Italia

­­­­­­­Presentazioni

• 2020    "RAS / MAPK pathway mutations are associated with adverse survival outcomes and may predict resistance to JAK inhibitors in myelofibrosis.” 25^th Annual edition of the European Hematology Association meeting. Presentazione orale

Premi e riconoscimenti

• 2019     ASH Abstract Award, " Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients,” 62^nd annual edition of the American Society of Hematology meeting

Finanziamenti

• 2018- In corso     Progetto MYNERVA (MYeloid NEoplasms Research Ven ture AIRC). Coordinatore: Prof. A.M. Vannucchi. Ruolo: Co-Investigator
• 2019 – In corso     Progetto E-MPN (European Myeloproliferative Neoplasms Network). Coordinatori: Prof. A. Reiter, Prof. C.N. Harrison. Ruolo: Co-Investigator
• 2023- In corso     Progetto PRIN (Progetti di Rilevante Interesse Nazionale) bando PNRR (Piano Nazionale di Ripresa e Resilienza) Under 40. Ruolo: Co-Principal Investigator

Studi clinici

• 2015 – In corso     Sub-investigator in oltre 20 trial clinici di fase I/II, III e IV, in particolare in pazienti con neoplasie mieloproliferative, condotti secondo GCP (god clinical practice)

Affiliazioni e professionali

• Società Italiana di Ematologia (SIE)
• European Hematology Association (EHA)

Capitoli e Libri

1. Coltro, G., Loscocco, G. G., & Vannucchi, A. M. (2021). Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. International review of cell and molecular biology, 365, 1-69.

Pubblicazioni

1. Guglielmelli, P., Maccari, C., Sordi, B., Balliu, M., Atanasio, A., Mannarelli, C., ..., Coltro, G., ..., & Vannucchi, A. M. (2023). Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis. Blood Cancer Journal, 13(1), 21.
2. Coltro, G., Sant'Antonio, E., Palumbo, G. A., Mannelli, F., De Stefano, V., Ruggeri, M., ... & Vannucchi, A. M. (2023). Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project. Cancer Medicine.
3. Coltro, G., Mannelli, F., Loscocco, G. G., Mannarelli, C., Rotunno, G., Maccari, C., ... & Guglielmelli, P. (2022). Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. Blood Cancer Journal, 12(8), 116.
4. Loscocco, G. G., Guglielmelli, P., Mannelli, F., Mora, B., Mannarelli, C., Rotunno, G., …, Coltro, G., ..., & Vannucchi, A. M. SF3B1 mutations in primary and secondary myelofibrosis: clinical, molecular and prognostic correlates. American journal of hematology.
5. Loscocco, G. G., Santi, R., Carrai, V., Coltro, G., Mannelli, F., Guglielmelli, P., & Vannucchi, A. M. (2022). Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis. International Journal of Laboratory Hematology.
6. Mannelli, F., Bencini, S., Coltro, G., Loscocco, G. G., Peruzzi, B., Rotunno, G., ... & Vannucchi, A. M. (2022). Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. American Journal of Hematology.
7. Guglielmelli, P., Coltro, G., Mannelli, F., Rotunno, G., Loscocco, G. G., Mannarelli, C., ... & Vannucchi, A. M. (2022). ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. Blood advances, 6(9), 2927-2931.
8. Guglielmelli, P., Loscocco, G. G., Mannarelli, C., Rossi, E., Mannelli, F., Ramundo, F., Coltro, G., ... & Vannucchi, A. M. (2021). JAK2V617F variant allele frequency> 50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer Journal, 11(12), 1-9.
9. Loscocco, G. G., Coltro, G., Guglielmelli, P., & Vannucchi, A. M. (2021). Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. Cells, 10(8), 1962.
10. Carr, R. M., Vorobyev, D., Lasho, T., Marks, D. L., Tolosa, E. J., Vedder, A., …, Coltro, G., ... & Patnaik, M. M. (2021). RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature communications, 12(1), 1-18.
11. Guglielmelli, P., Gangat, N., Coltro, G., Lasho, T. L., Loscocco, G. G., Finke, C. M., ... & Tefferi, A. (2021). Mutations and thrombosis in essential thrombocythemia. Blood cancer journal, 11(4), 1-4.
12. Coltro, G., & Vannucchi, A. M. (2021). The safety of JAK kinase inhibitors for the treatment of myelofibrosis. Expert Opinion on Drug Safety, 20(2), 139-154.
13. Mangaonkar, A. A., Reichard, K. K., Binder, M., Coltro, G., Lasho, T. L., Carr, R. M., ... & Patnaik, M. M. (2020). Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood advances, 4(21), 5425-5430.
14. Coltro, G., Rotunno, G., Mannelli, L., Mannarelli, C., Fiaccabrino, S., Romagnoli, S., ... & Patnaik, M. M. (2020). RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Advances, 4(15), 3677-3687.
15. Buradkar, A., Bezerra, E., Coltro, G., Lasho, T. L., Finke, C. M., Gangat, N., ... & Khan, S. (2020). Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia, 1-6.
16. Antelo, G., Mangaonkar, A. A., Coltro, G., Buradkar, A., Lasho, T. L., Finke, C., ... & Elliott, M. A. (2020). Response to erythropoiesis‐stimulating agents in patients with WHO‐defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T). British journal of haematology, 189(3), e104-e108.
17. Coltro, G., Mangaonkar, A. A., Lasho, T. L., Finke, C. M., Pophali, P., Carr, R., ... & Robertson, K. D. (2019). Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients. Leukemia, 1-15.
18. Tefferi, A., Guglielmelli, P., Lasho, T. L., Coltro, G., Finke, C. M., Loscocco, G. G., ... & Hanson, C. A. (2020). Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. British journal of haematology, 189(2), 291-302.
19. Guglielmelli, P., Carobbio, A., Rumi, E., De Stefano, V., Mannelli, L., Mannelli, F., Rotunno, G., Coltro, G., ... & Finazzi, M. C. (2020). Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood cancer journal, 10(2), 1-8.
20. Coltro, G., Mannelli, F., Vergoni, F., Santi, R., Massi, D., Siliani, L. M., ... & Paoli, C. (2020). Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. Clinical and Experimental Medicine, 1-8.
21. DiFilippo, E. C., Coltro, G., Carr, R. M., Mangaonkar, A. A., Binder, M., Khan, S. P., ... & Chen, D. (2020). Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia, 1-6.
22. Li, M., Shah, M., Binder, M., Lasho, T., Carr, R., Mangaonkar, A., Gangat, N., Coltro, G., ... & Patnaik, M. M. (2020). Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. American journal of hematology, 95(2), E31-E34.
23. Mangaonkar, A. A., Swoboda, D. M., Coltro, G., Lasho, T. L., Novotny, P. J., Pophali, P., ... & Al-Kali, A. (2019). Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia, 1-6.
24. Coltro, G., Antelo, G., Lasho, T. L., Finke, C. M., Pardanani, A., Gangat, N., ... & Fernandez-Zapico, M. E. (2020). Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. American journal of hematology.
25. Coltro, G., & Patnaik, M. M. (2019). Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. Current Oncology Reports, 21(11), 101.
26. Guglielmelli, P., Pacilli, A., Coltro, G., Mannelli, F., Mannelli, L., Contini, E., ... & Scocco, G. L. (2019). Characteristics and clinical correlates of NFE2 mutations in Chronic Myeloproliferative Neoplasms. American journal of hematology.
27. Tischer, A., Antelo, G., Coltro, G., Finke, C. M., Gonsalves, W., Pardanani, A., ... & Patnaik, M. M. (2019). Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia research, 87, 106264.
28. Coltro, G., Lasho, T. L., Finke, C. M., Gangat, N., Pardanani, A., Tefferi, A., ... & Patnaik, M. M. (2019). Germline SH2B3 Pathogenic Variant Associated with Myelodysplastic syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis. American journal of hematology.
29. Loscocco, G. G., Mannelli, F., Guglielmelli, P., Paoli, C., Marone, I., Cucci, R., Coltro, G., ... & De Stefano, V. (2019). Italian survey on clinical practice in Myeloproliferative Neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. American journal of hematology.
30. Tefferi, A., Betti, S., Barraco, D., Mudireddy, M., Shah, S., Hanson, C. A., …, Coltro, G., ... & Guglielmelli, P. (2017). Gender and survival in essential thrombocythemia: A two‐center study of 1,494 patients. American journal of hematology, 92(11), 1193-1197.
31. Coltro, G., Mannelli, F., Guglielmelli, P., Pacilli, A., Bosi, A., & Vannucchi, A. M. (2017). A life‐threatening ruxolitinib discontinuation syndrome. American journal of hematology, 92(8), 833-838.
32. Bertozzi, I., Peroni, E., Coltro, G., Bogoni, G., Cosi, E., Santarossa, C., ... & Randi, M. L. (2016). Thrombotic risk correlates with mutational status in true essential thrombocythemia. European journal of clinical investigation, 46(8), 683-689.

­­­­­­­­Education

• 2019     Hematology Specialty, 60/60 cum laude, University of Florence, Italy. Thesis: Clinical, Molecular and Prognostic Correlates of Number, Type and Intragenic Localization of TET2 Mutations in Chronic Myelomonocytic Leukemia. Thesis Advisors: Prof. A.M. Vannucchi, MD

• 2015     Medical Doctor, 110/110 cum laude, University of Padua, Italy. Thesis: CALR Mutations: Sequencing and Clinical Implications in Essential Thrombocythemia. Thesis Advisors: Prof. M.L. Randi, MD

Residency and Fellowship Training

• 2019                 Research Residency at Mayo Clinic, Rochester, MN (USA). Advisors: Dr. Ayalew Tefferi, Dr. Mrinal Patnaik
• 2015 - 2019      Hematology Residency, University of Florence, Italy

Employment

• 2021 - Present  Type-A Research Fellowship, University of Florence, Italy
• 2020 - 2021      Research Fellowship, University of Florence, Italy

Scientific interests

• Philadelphia-negative chronic myeloproliferative neoplasms (experimental and clinical)
• Molecular characterization of gene expression profile in patients with myeloproliferative neoplasms
• Preclinical and clinical studies with innovative drugs in patients with myeloproliferative neoplasms

Relevant skills

• Diagnosis and treatment of patients with oncological and non-oncological hematological diseases, particularly in the management of patients with chronic myeloproliferative neoplasms.
• Experience in BSL1, BSL2 and clean rooms, preparation of cell cultures in suspension and adhesion (cell lines and primary patient cells), isolation of specific cell populations by density gradient separation, extraction of nucleic acids from tissue, cell pellets and whole blood, purification and quantification, immunoprecipitation and western blotting, ELISA and immunohistochemistry, PCR, qRT-PCR, HRM, Sanger sequencing.
• Use of statistical software (SPSS, GraphPad, JMP, R) and bioinformatics tools. Good knowledge of online databases in genomics, transcriptomics and proteomics.
• Excellent relationship and collaboration skills with all professional figures. Excellent ability to develop and discuss problems and results of clinical and research activities, autonomously organize clinical and experimental work, and define priorities within set deadlines.

Teaching experience

• 2020-Present    Blood diseases, School of Medicine, University of Florence, Italy
• 2020-Present    Blood diseases, Course of Biotechnology, University of Florence, Italy
• 2020-Present    Blood diseases, Course of Nursing, University of Florence, Italy

­­­­­­­Presentations

• 2020     "RAS / MAPK pathway mutations are associated with adverse survival outcomes and may predict resistance to JAK inhibitors in myelofibrosis.” 25^th Annual edition of the European Hematology Association meeting. Oral presentation.

Awards and honors

• 2019     ASH Abstract Award, " Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients,” 62^nd annual edition of the American Society of Hematology meeting.

Research funding

• 2018- Present   MYNERVA (MYeloid NEoplasms Research Ven ture AIRC) project. Coordinator: Prof. A.M. Vannucchi. Role: Co-Investigator 
• 2019 - Present  E-MPN (European Myeloproliferative Neoplasms Network) project. Coordinators: Prof. A. Reiter, Prof. C.N. Harrison. Role: Co-Investigator
• 2023 - PRIN (Progetti di Rilevante Interesse Nazionale) project - PNRR (Piano Nazionale di Ripresa e Resilienza) Under 40. Role: Co-Principal Investigator

Clinical trials

• 2015 – Present  Sub-investigator in >20 Phase I/II, Phase II and Phase III clinical trials, particularly in patients with myeloproliferative neoplasms, conducted according to the GCP

Professional affiliations and memberships

• Italian Society of Hematology (SIE)
• European hematology association (EHA)

Book Chapters

1. Coltro, G., Loscocco, G. G., & Vannucchi, A. M. (2021). Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. International review of cell and molecular biology, 365, 1-69.

­­­

Publications

1. Guglielmelli, P., Maccari, C., Sordi, B., Balliu, M., Atanasio, A., Mannarelli, C., ..., Coltro, G., ..., & Vannucchi, A. M. (2023). Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis. Blood Cancer Journal, 13(1), 21.
2. Coltro, G., Sant'Antonio, E., Palumbo, G. A., Mannelli, F., De Stefano, V., Ruggeri, M., ... & Vannucchi, A. M. (2023). Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project. Cancer Medicine.
3. Coltro, G., Mannelli, F., Loscocco, G. G., Mannarelli, C., Rotunno, G., Maccari, C., ... & Guglielmelli, P. (2022). Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. Blood Cancer Journal, 12(8), 116.
4. Loscocco, G. G., Guglielmelli, P., Mannelli, F., Mora, B., Mannarelli, C., Rotunno, G., …, Coltro, G., ..., & Vannucchi, A. M. SF3B1 mutations in primary and secondary myelofibrosis: clinical, molecular and prognostic correlates. American journal of hematology.
5. Loscocco, G. G., Santi, R., Carrai, V., Coltro, G., Mannelli, F., Guglielmelli, P., & Vannucchi, A. M. (2022). Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis. International Journal of Laboratory Hematology.
6. Mannelli, F., Bencini, S., Coltro, G., Loscocco, G. G., Peruzzi, B., Rotunno, G., ... & Vannucchi, A. M. (2022). Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. American Journal of Hematology.
7. Guglielmelli, P., Coltro, G., Mannelli, F., Rotunno, G., Loscocco, G. G., Mannarelli, C., ... & Vannucchi, A. M. (2022). ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. Blood advances, 6(9), 2927-2931.
8. Guglielmelli, P., Loscocco, G. G., Mannarelli, C., Rossi, E., Mannelli, F., Ramundo, F., Coltro, G., ... & Vannucchi, A. M. (2021). JAK2V617F variant allele frequency> 50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer Journal, 11(12), 1-9.
9. Loscocco, G. G., Coltro, G., Guglielmelli, P., & Vannucchi, A. M. (2021). Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. Cells, 10(8), 1962.
10. Carr, R. M., Vorobyev, D., Lasho, T., Marks, D. L., Tolosa, E. J., Vedder, A., …, Coltro, G., ... & Patnaik, M. M. (2021). RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature communications, 12(1), 1-18.
11. Guglielmelli, P., Gangat, N., Coltro, G., Lasho, T. L., Loscocco, G. G., Finke, C. M., ... & Tefferi, A. (2021). Mutations and thrombosis in essential thrombocythemia. Blood cancer journal, 11(4), 1-4.
12. Coltro, G., & Vannucchi, A. M. (2021). The safety of JAK kinase inhibitors for the treatment of myelofibrosis. Expert Opinion on Drug Safety, 20(2), 139-154.
13. Mangaonkar, A. A., Reichard, K. K., Binder, M., Coltro, G., Lasho, T. L., Carr, R. M., ... & Patnaik, M. M. (2020). Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood advances, 4(21), 5425-5430.
14. Coltro, G., Rotunno, G., Mannelli, L., Mannarelli, C., Fiaccabrino, S., Romagnoli, S., ... & Patnaik, M. M. (2020). RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Advances, 4(15), 3677-3687.
15. Buradkar, A., Bezerra, E., Coltro, G., Lasho, T. L., Finke, C. M., Gangat, N., ... & Khan, S. (2020). Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia, 1-6.
16. Antelo, G., Mangaonkar, A. A., Coltro, G., Buradkar, A., Lasho, T. L., Finke, C., ... & Elliott, M. A. (2020). Response to erythropoiesis‐stimulating agents in patients with WHO‐defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T). British journal of haematology, 189(3), e104-e108.
17. Coltro, G., Mangaonkar, A. A., Lasho, T. L., Finke, C. M., Pophali, P., Carr, R., ... & Robertson, K. D. (2019). Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients. Leukemia, 1-15.
18. Tefferi, A., Guglielmelli, P., Lasho, T. L., Coltro, G., Finke, C. M., Loscocco, G. G., ... & Hanson, C. A. (2020). Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. British journal of haematology, 189(2), 291-302.
19. Guglielmelli, P., Carobbio, A., Rumi, E., De Stefano, V., Mannelli, L., Mannelli, F., Rotunno, G., Coltro, G., ... & Finazzi, M. C. (2020). Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood cancer journal, 10(2), 1-8.
20. Coltro, G., Mannelli, F., Vergoni, F., Santi, R., Massi, D., Siliani, L. M., ... & Paoli, C. (2020). Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. Clinical and Experimental Medicine, 1-8.
21. DiFilippo, E. C., Coltro, G., Carr, R. M., Mangaonkar, A. A., Binder, M., Khan, S. P., ... & Chen, D. (2020). Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia, 1-6.
22. Li, M., Shah, M., Binder, M., Lasho, T., Carr, R., Mangaonkar, A., Gangat, N., Coltro, G., ... & Patnaik, M. M. (2020). Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. American journal of hematology, 95(2), E31-E34.
23. Mangaonkar, A. A., Swoboda, D. M., Coltro, G., Lasho, T. L., Novotny, P. J., Pophali, P., ... & Al-Kali, A. (2019). Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia, 1-6.
24. Coltro, G., Antelo, G., Lasho, T. L., Finke, C. M., Pardanani, A., Gangat, N., ... & Fernandez-Zapico, M. E. (2020). Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. American journal of hematology.
25. Coltro, G., & Patnaik, M. M. (2019). Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. Current Oncology Reports, 21(11), 101.
26. Guglielmelli, P., Pacilli, A., Coltro, G., Mannelli, F., Mannelli, L., Contini, E., ... & Scocco, G. L. (2019). Characteristics and clinical correlates of NFE2 mutations in Chronic Myeloproliferative Neoplasms. American journal of hematology.
27. Tischer, A., Antelo, G., Coltro, G., Finke, C. M., Gonsalves, W., Pardanani, A., ... & Patnaik, M. M. (2019). Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia research, 87, 106264.
28. Coltro, G., Lasho, T. L., Finke, C. M., Gangat, N., Pardanani, A., Tefferi, A., ... & Patnaik, M. M. (2019). Germline SH2B3 Pathogenic Variant Associated with Myelodysplastic syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis. American journal of hematology.
29. Loscocco, G. G., Mannelli, F., Guglielmelli, P., Paoli, C., Marone, I., Cucci, R., Coltro, G., ... & De Stefano, V. (2019). Italian survey on clinical practice in Myeloproliferative Neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. American journal of hematology.
30. Tefferi, A., Betti, S., Barraco, D., Mudireddy, M., Shah, S., Hanson, C. A., …, Coltro, G., ... & Guglielmelli, P. (2017). Gender and survival in essential thrombocythemia: A two‐center study of 1,494 patients. American journal of hematology, 92(11), 1193-1197.
31. Coltro, G., Mannelli, F., Guglielmelli, P., Pacilli, A., Bosi, A., & Vannucchi, A. M. (2017). A life‐threatening ruxolitinib discontinuation syndrome. American journal of hematology, 92(8), 833-838.
32. Bertozzi, I., Peroni, E., Coltro, G., Bogoni, G., Cosi, E., Santarossa, C., ... & Randi, M. L. (2016). Thrombotic risk correlates with mutational status in true essential thrombocythemia. European journal of clinical investigation, 46(8), 683-689.